



The association between neurohormonal therapy and mortality in older adults with heart failure with reduced ejection fraction

Lauren Gilstrap MD, MPH^{1,2}  | Andrea M. Austin PhD² |
Barbara Gladders MS¹ | Parag Goyal MD, MSc³  | A. James O'Malley PhD² |
Amber Barnato MD, MPH² | Anna N. A. Tosteson ScD² | Jonathan S. Skinner PhD²

¹Heart and Vascular Center, Section of Cardiology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA

²The Dartmouth Institute, Geisel School of Medicine, Hanover, New Hampshire, USA

³Division of Cardiology, Weill Cornell Medical Center, New York, New York, USA

Correspondence

Lauren Gilstrap, The Dartmouth Institute, 1 Medical Center Road, Lebanon, NH 03766, USA.

Email: lauren.g.gilstrap@dartmouth.edu

Funding information

American Heart Association, Grant/Award Number: 18IPA34170185; National Center for Advancing Translational Sciences, Grant/Award Number: UL1TR001086; National Heart, Lung, and Blood Institute, Grant/Award Number: K23HL142835; National Institute on Aging, Grant/Award Number: P01AG019783

Abstract

Background/Objectives: Neurohormonal therapy, which includes beta-blockers and angiotensin-converting enzyme inhibitor/angiotensin receptor blockers (ACEi/ARBs), is the cornerstone of heart failure with reduced ejection fraction (HFrEF) treatment. While neurohormonal therapies have demonstrated efficacy in randomized clinical trials, older patients, which now comprise the majority of HFrEF patients, were underrepresented in those original trials. This study aimed to determine the association between short- (30 day) and long-term (1 year) mortality and the use of neurohormonal therapy in HFrEF patients, across the age spectrum.

Design/Setting/Participants: This is a population-based, retrospective, cohort study between January 2008 and December 2015. We used 100% Medicare Parts A and B and a random 40% sample of Part D to create a cohort of 295,494 fee-for-service beneficiaries with at least one hospitalization for HFrEF between 2008 and 2015. All analyses were performed between May 2019 and July 2020.

Exposure: We used Part D data to determine exposure to beta-blocker and ACEi and ARB therapy.

Results: We found that in 295,494 patients admitted for HFrEF between 2008 and 2015, the average age was 80 years, 54% were female and 17% were non-white. The baseline mortality rate was higher among those aged ≥ 85 , but the mortality benefits of neurohormonal therapy were preserved across the age spectrum. Among those ≥ 85 years old, the hazard ratio for death within 30 days was 0.59 (95% confidence interval [CI] 0.56–0.62; $p < 0.001$) for beta-blockers and 0.47 (95% CI 0.44–0.49; $p < 0.001$) for ACEi/ARBs. The hazard ratio for death within 1 year was 0.37–0.56 (95% CI 0.35–0.58; $p < 0.001$) for beta-blockers and 0.38–0.53 (95% CI 0.37–0.55; $p < 0.001$) for ACEi/ARB.

Conclusion: At a population level, neurohormonal therapy was associated with lower short- and long-term mortality across the age spectrum.

KEYWORDS

aging, heart failure, pharmacology, quality and outcomes

INTRODUCTION

Neurohormonal therapy, which includes beta-blockers and angiotensin-converting inhibitors (ACEi)/angiotensin receptor blockers (ARBs), is a cornerstone of therapy for patients with heart failure with reduced ejection fraction (HFrEF).^{1–3} As a result, use of neurohormonal therapy after an admission for HFrEF and then continued over time is recommended by current guidelines⁴ and forms the basis for HFrEF performance measures⁵ and quality metrics.⁶ An important limitation of the original trials of neurohormonal therapy, upon which current guidelines and quality measures rest, however, was that those studies enrolled relatively young patients (average age 50–60 years) with few comorbidities.^{1–3,7,8} Today, over half of Medicare's heart failure population is ≥ 75 years old and over two thirds have multiple chronic conditions.⁹ Given the rising age of Medicare beneficiaries, the increasing incidence of heart failure in the older adults, and the significant heterogeneity that exists within the older heart failure population, there is a pressing need to understand the role that age plays in a patients' response to neurohormonal therapy.

As patients age, their potential for the long-term mortality benefits decreases. At the same time, their risk for short-term adverse events increases due to age-related physiologic changes as well as the concurrence of geriatric conditions such as frailty and cognitive impairment which increase the risk of adverse drug events.¹⁰ Because large-scale clinical trials of neurohormonal therapy, specifically in older adults, are unlikely to ever be done, the aim of this study is to use Medicare claims data to describe the risks and benefit trade-offs of neurohormonal therapy after HFrEF hospitalization and the variation by age.

METHODS

The authors declare that all supporting data are available within the article and its online supplementary files. This study was approved by the Institutional Review Board at Dartmouth College. This study is also compliant with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for retrospective cohort studies.

Key Points

- Neurohormonal therapy, which includes beta-blockers and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor-neprilysin inhibitor (ACEi/ARB/ARNI), are prescribed at lower rates among older adults with heart failure with reduced ejection fraction (HFrEF) as compared to similar, younger patients.
- Despite concern that a higher risk of side effects might alter the net risk/benefit ratio for these therapies in older HFrEF patients, the benefits of neurohormonal therapy do not decrease with increasing age.

Why Does this Paper Matter?

Absent a strong clinical contraindication, beta-blockers and ACEi/ARBs should at least be trialed in all HFrEF patients, regardless of age, and efforts should be made to increase their use among eligible, older adults with HFrEF.

Study population

We used the 100% national sample of patients enrolled in both Medicare Parts A and B and a random 40% sample of Part D enrollment to create a cohort of fee-for-service (FFS) beneficiaries with at least one hospitalization (index admission) for HFrEF between 2008 and 2015. Only the patient's first hospitalization for HFrEF during the study period was included to avoid overrepresenting readmitted patients. HFrEF was defined using International Classification of Diseases (ICD) 9 and 10 codes and a methodology based on previously validated studies (Table S1).^{11,12} We required 1 year of FFS coverage prior to the index HFrEF admission to determine comorbidities and 1 year of FFS coverage after discharge (through 2016) to determine drug exposure and outcomes.

Patients who died during admission were excluded as were those that underwent cardiac transplant, or placement of a durable mechanical circulatory support (MCS) device during their index admission and those admitted from or discharged to hospice or with home intravenous

inotropes (not including digoxin). Patients with previously placed, durable MCS devices or a prior cardiac transplant were also excluded.

For the study population, we determined patient age, sex, race/ethnicity, dual-enrollment status, and disability status directly from the enrollment file. Zip-code level estimates for socioeconomic variables were obtained using the patient's zip-code and 5-year estimates from the 2012 American Community Survey data.¹³ Patient geography was ascertained using the patient's zip-code and the Centers for Disease Control's census regions.¹⁴ Comorbidities were determined using the Elixhauser comorbidity algorithm.¹⁵ Prior hospitalizations and procedures were determined using Part A data and other drug exposure was determined using Part D data.

Exposure

We used Part D data to determine exposure to neurohormonal therapy. Neurohormonal therapy included beta blockers, ACE inhibitors and ARBs. Beta blockers included metoprolol succinate, bisoprolol, and carvedilol. ACE inhibitors included benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, and trandolapril. ARBs included valsartan, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, and telmisartan. Sacubitril/Valsartan was included after its approval by the Food and Drug Administration in July 2015.

For the short-term, 30-day analysis, we defined drug exposure as binary based on whether or not there was a fill for the drug within 30 days of discharge. Over 50% of fills were made in the first 5 days after discharge (Figure S1). For the long-term, 1-year, analysis, we measured drug exposure over time using the proportion of days covered (PDC).¹⁶ We separated patients into three exposure groups: "No" exposure (0 PDC), "moderate" exposure (1–80 PDC), and "high" exposure (80+ PDC) based on the threshold for adherence being 80 PDC.¹⁶

Outcomes

The short-term outcome of interest is all-cause death within 30 days of hospital discharge. Long-term outcomes included time to all-cause death within 365 days, conditional on survival to 30 days postdischarge. Death was determined using the master beneficiary summary file.

Statistical methods

Inverse probability weighting was used to balance the observed characteristics (Table 1) across the exposure

groups at baseline (prior to follow-up) in each of the analyses.¹⁷ After weighting, there were no clinically significant differences between exposed and unexposed patients on any of the measurable covariates (Table S2). For the short-term analysis, we used inverse probability weighted logistic regression to compare death rates between patients who either did or did not fill a prescription for beta-blocker or ACEi/ARB within 30 days of discharge. For the long-term analysis, we used an inverse probability weighted time-to-event analysis to compare the time-to-death between Days 30 and 365 postdischarge between patients in three PDC groups. Errors were clustered by the hospital referral region. A *p*-value of <0.05 was considered significant. All hypotheses were tested using two-sided tests. All analyses were performed between May 2019 and July 2020 using SAS version 9.4, Cary, North Carolina.

RESULTS

Baseline characteristics

Baseline characteristics of the 295,494 patients in the HFREF cohort, stratified by neurohormonal therapy exposure after HFREF hospitalization, are displayed in Table 1. The mean age across all groups was 80 years. Across all exposure groups, the majority of patients were female (52%–56%) and white (81%–85%). Thirty-four percent of patients were dually eligible for Medicaid and this did not vary across exposure groups. Over 50% of patients had at least one hospitalization in the year prior and over 53% had four or more concurrent comorbidities. The average frailty score was 0.20–0.22 ± 0.06–0.07.¹⁸ Approximately 7% of patients had hypotension during their index admission; 5% had bradycardia and 20% had acute kidney injury. The average number of drugs prescribed at discharge was 5.5 ± 3.3.

Use rates of both beta-blockers and ACEi/ARBs after hospital discharge were low. Forty-nine percent of patients filled a beta-blocker within 30 days of discharge and 39% filled an ACEi/ARB. Among those age 85+, only 42% received a beta-blocker and 32% received an ACEi/ARB. During the year following discharge, 42% of patients aged 85+ years had no beta-blocker exposure and 41% had no ACEi/ARB exposure.

The 30-day mortality rates among those who filled a beta-blocker within 30 days of discharge was 1.9%–4.3% (Table 2), with the oldest patients having the highest mortality rate. Among those without a beta-blocker fill, the 30-day mortality rate was ranged from 6.1% to 12.7% (*p* < 0.001 across all three age strata). The number needed to treat (NNT) to prevent one death at 30 days

TABLE 1 Baseline characteristics of patients based on beta-blocker and ACEi/ARB exposure after HFREF hospitalization, 2008–2015

	Beta-blocker exposure N/mean (%/SD)			ACEi/ARB/ARNI exposure N/mean (%/SD)		
	No exposure (0 PDC)	Some exposure (1–80 PDC)	High exposure (80+ PDC)	No exposure (0 PDC)	Some exposure (1–80 PDC)	High exposure (80+ PDC)
N	82,183 (27.8)	104,898 (35.5)	108,413 (36.7)	113,102 (38.3)	101,844 (34.5)	80,548 (27.3)
Demographic characteristics						
Mean age	82.0 (8.3)	79.6 (8.0)	79.5 (8.0)	81.8 (8.2)	79.3 (8.0)	79.2 (8.0)
Age category						
66–74	17,718 (21.6)	32,042 (30.5)	33,627 (31.0)	25,133 (22.2)	32,372 (31.8)	25,882 (32.1)
75–84	30,031 (36.5)	41,546 (39.6)	42,976 (39.6)	42,175 (37.3)	40,499 (39.8)	31,879 (39.6)
85+	34,434 (41.9)	31,310 (29.8)	31,810 (29.3)	45,794 (40.5)	28,973 (28.4)	22,787 (28.3)
Sex						
Male	36,256 (44.1)	50,269 (47.9)	50,556 (46.6)	53,678 (47.5)	47,661 (46.8)	35,742 (44.4)
Female	45,927 (55.9)	54,629 (52.1)	57,857 (53.4)	59,424 (52.5)	54,183 (53.2)	44,806 (55.6)
Race/Ethnicity						
White	70,102 (85.3)	84,804 (80.8)	90,537 (83.5)	97,235 (86.0)	82,351 (80.9)	65,857 (81.8)
Black	6384 (7.8)	11,383 (10.9)	9230 (8.5)	8730 (7.7)	10,707 (10.5)	7560 (9.4)
Hispanic	3650 (4.4)	5833 (5.6)	5532 (5.1)	4457 (3.9)	5817 (5.7)	4741 (5.9)
Other	2047 (2.5)	2878 (2.7)	3114 (2.9)	2680 (2.4)	2969 (2.9)	2390 (3.0)
Socioeconomic characteristics						
Dual eligibility	29,115 (35.4)	35,894 (34.2)	36,406 (33.6)	37,550 (33.2)	35,314 (34.7)	28,551 (35.4)
% Bachelor's degree ^a	26.8 (15.7)	26.7 (15.6)	27.2 (15.7)	27.3 (15.7)	26.5 (15.5)	27.0 (15.7)
% Below federal poverty line ^a	15.7 (9.1)	16.0 (9.5)	15.5 (9.2)	15.4 (9.1)	16.1 (9.4)	15.8 (9.4)
Geography						
Midwest	20,776 (25.3)	26,668 (25.4)	30,007 (27.7)	29,499 (26.1)	26,157 (25.7)	21,795 (27.1)
Northeast	17,218 (21.0)	21,267 (20.3)	24,174 (22.3)	25,311 (22.4)	19,859 (19.5)	17,489 (21.7)
South	33,103 (40.3)	43,194 (41.2)	40,469 (37.3)	44,229 (39.1)	41,973 (41.2)	30,564 (37.9)
West	11,086 (13.5)	13,769 (13.1)	13,763 (12.7)	14,063 (12.4)	13,855 (13.6)	10,700 (13.3)
Medical comorbidities ^b						
≤ 3 Elixhauser comorbidities	35,647 (43.4)	48,978 (46.7)	55,781 (51.5)	45,526 (40.3)	50,124 (49.2)	44,756 (55.6)
≥ 4 Elixhauser comorbidities	46,536 (56.6)	55,920 (53.3)	52,632 (48.5)	67,576 (59.7)	51,720 (50.8)	35,792 (44.4)
Frailty score	0.22 (0.07)	0.21 (0.06)	0.20 (0.06)	0.22 (0.07)	0.21 (0.06)	0.20 (0.06)
Implantable cardiac defibrillator	8163 (9.9)	15,914 (15.2)	15,404 (14.2)	14,234 (12.6)	14,801 (14.5)	10,446 (13.0)
Index admission comorbidities ^c						
Hypotension	6265 (7.6)	7150 (6.8)	7462 (6.9)	9546 (8.4)	6556 (6.4)	4775 (5.9)
Bradycardia	4394 (5.3)	5265 (5.0)	5848 (5.4)	5727 (5.1)	5362 (5.3)	4418 (5.5)
Acute kidney injury	16,523 (20.1)	20,513 (19.6)	20,696 (19.1)	29,225 (25.8)	17,570 (17.3)	10,937 (13.6)
Medication use prior to admission ^d						
0 PDC	62,825 (76.4)	41,765 (39.8)	37,210 (34.3)	83,582(73.9)	41,232 (40.5)	24,240 (30.1)
1–79 PDC	15,077 (18.3)	48,813 (46.5)	47,527 (43.8)	27,084 (23.9)	55,881 (54.9)	51,246 (63.6)
80+ PDC	4281 (5.2)	14,320 (13.7)	23,676 (21.8)	2436 (2.2)	4731 (4.6)	5062 (6.3)
Total number of drugs at discharge	4.0 (3.6)	5.5 (3.4)	6.9 (2.9)	4.5 (3.6)	5.8 (3.3)	6.9 (2.8)
All-cause hospitalizations in year prior						
0 Hospitalizations	36,145 (44.0)	48,573 (46.3)	56,402 (52.0)	48,079 (42.5)	49,432 (48.5)	43,609 (54.1)
1–2 Hospitalizations	21,562 (26.2)	26,872 (25.6)	26,715 (24.6)	29,832 (26.4)	25,765 (25.3)	19,552 (24.3)

TABLE 1 (Continued)

	Beta-blocker exposure N/mean (%/SD)			ACEi/ARB/ARNI exposure N/mean (%/SD)		
	No exposure (0 PDC)	Some exposure (1–80 PDC)	High exposure (80+ PDC)	No exposure (0 PDC)	Some exposure (1–80 PDC)	High exposure (80+ PDC)
3+ Hospitalizations	24,476 (29.8)	29,453 (28.1)	25,296 (23.3)	35,191 (31.1)	26,647 (26.2)	17,387 (21.6)

Abbreviations: ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; ARNI, angiotensin receptor-neprilysin inhibitor; MRA, mineralocorticoid receptor antagonists; PDC, percentage of days covered.

^aZCTA-level characteristics derived from linking beneficiary zip codes with US Census Data.

^bIndividual Elixhauser comorbidities are included in inverse probability weighting.

^cRelevant comorbidities that might impact use of neurohormonal therapy.

^dBeta-blocker use prior to admission for beta blocker exposure group, ACEi/ARB/ARNI use prior to admission for ACEi/ARB/ARNI exposure group.

TABLE 2 Unadjusted 30-day and 1-year^a mortality rates after first hospitalization for heart failure with reduced ejection fraction based on age and neurohormonal therapy use after discharge, 2008–2015

	Age 66–74 years	Age 75–84 years	Age 85+ years
30-day mortality			
Beta-blockers			
No fill within 30 days	2289 (6.1)	4739 (8.2)	7147 (12.7)
Fill within 30 days	885 (1.9)	1440 (2.5)	1795 (4.3)
Number needed to treat (30-day mortality)	24	18	12
ACEi/ARB/ARNI			
No fill within 30 days	2581 (5.7)	5288 (7.7)	7739 (11.9)
Fill within 30 days	593 (1.6)	891 (1.9)	1203 (3.7)
Number needed to treat (30-day mortality)	24	17	12
1-year mortality ^a			
Beta-blocker exposure			
No exposure (0 PDC)	4667 (26.3)	9513 (31.7)	13,484 (39.2)
Any exposure (1+ PDC)	10,601 (16.2)	18,318 (21.7)	20,714 (32.9)
Number needed to treat (1-year mortality)	10	10	16
ACEi/ARB/ARNI exposure			
No exposure (0 PDC)	7005 (27.9)	14,129 (33.5)	18,756 (41.0)
Any exposure (1+ PDC)	8263 (14.0)	13,702 (18.7)	15,442 (29.4)
Number needed to treat (1-year mortality)	7	7	9

Abbreviations: ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; ARNI, angiotensin receptor-neprilysin inhibitor; PDC, percentage of days covered.

^aConditional on survival to 30 days after discharge.

with beta-blockers ranged from 12 to 24. The 30-day mortality rate among those who filled an ACEi/ARB was 1.6%–3.7%, compared to 5.7%–11.9% among those who did not. The NNT to prevent one death at 30 days with ACEi/ARB was 12–24. The 1-year mortality rates ranged from 16.2% to 32.9% among those with any beta-blocker exposure and from 26.3% to 39.2% among those with no exposure. The NNT to prevent one death at 1 year (conditional on survival to 30 days) was 10–16. The 1-year mortality rates ranged from 14.2% to 29.8% among those with any ACEi/ARB exposure and from 27.9% to 41% for those

without no ACEi/ARB exposure. The NNT ranged from 7 to 9.

Short-term analysis (30-day mortality)

There was a significantly decreased odds of death within 30 days after HFrEF discharge among patients who filled a prescription for neurohormonal therapy, across all age strata (Table 3). In the 66–74 age stratum, the odds ratio (OR) for death within 30 days was 0.68 (95% confidence

TABLE 3 Odds of death within 30 days of hospital discharge based on neurohormonal drug fill status, stratified by age, 2008–2015

Drug fill within 30 days of discharge	Odds ratio	95% Confidence interval	p-Value
Beta blocker fill			
Age 66–74	0.68	0.63–0.74	<0.001
Age 75–84	0.65	0.61–0.69	<0.001
Age 85+	0.59	0.56–0.62	<0.001
ACEi/ARB/ARNI fill			
Age 66–74	0.53	0.48–0.58	<0.001
Age 75–84	0.46	0.43–0.49	<0.001
Age 85+	0.47	0.44–0.49	<0.001

Abbreviations: ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; ARNI, angiotensin receptor-neprilysin inhibitor.

	Hazard ratio	95% Confidence interval	p-Value
Beta blocker exposure			
Age 66–74			
1–80 PDC	0.46	0.44–0.49	<0.001
80+ PDC	0.37	0.35–0.39	<0.001
Age 75–84			
1–80 PDC	0.49	0.47–0.51	<0.001
80+ PDC	0.39	0.37–0.40	<0.001
Age 85+			
1–80 PDC	0.56	0.54–0.58	<0.001
80+ PDC	0.43	0.42–0.45	<0.001
ACEi/ARB/ARNI exposure			
Age 66–74			
1–80 PDC	0.43	0.42–0.45	<0.001
80+ PDC	0.39	0.37–0.41	<0.001
Age 75–84			
1–80 PDC	0.45	0.44–0.47	<0.001
80+ PDC	0.38	0.37–0.40	<0.001
Age 85+			
1–80 PDC	0.53	0.52–0.55	<0.001
80+ PDC	0.45	0.43–0.47	<0.001

TABLE 4 Hazard ratios for death within 1 year^a after hospital discharge based on neurohormonal drug exposure, stratified by age, 2008–2015^b

Note: PDC is proportion of days covered which is the number of days “covered by drug” based on Part D prescription fills over the number of days in the follow-up period. No beta-blocker exposure and no ACEi/ARB exposure is the reference group.

Abbreviations: ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; ARNI, angiotensin receptor-neprilysin inhibitor; PDC, percentage of days covered.

^aConditional on survival to 30 days after discharge.

^bErrors are clustered at the hospital referral region level.

interval [CI] 0.63–0.74; $p < 0.001$) among those patients that filled a prescription for beta-blockers and OR 0.53 (95% CI 0.48–0.58; $p < 0.001$) among those patients that filled a prescription for ACEi/ARBs, compared to patients who do not fill a prescription for the respective drug classes. In the 85+ age stratum, there was a significantly

decreased odds of death among those who filled prescriptions for beta-blockers (OR 0.59; 95% CI 0.56–0.58; $p < 0.001$) and ACEi/ARBs (OR 0.47; 95% CI 0.44–0.49; $p < 0.001$) compared to those who did not. To guard against immortal time bias, we also ran the short-term analysis as a “target trial” with a narrow exposure

window of 7 days after discharge and found a similar benefit, preserved in magnitude across the age spectrum (Table S3).

Long-term analysis (1-year mortality)

There was also a significantly decreased risk of death within 1 year among patients exposed to at least some neurohormonal therapy, across the age spectrum (Table 4). In the 66–74 age stratum, there was a similar decrease in the risk of death among those with moderate beta-blocker exposure (hazard ratio [HR] 0.46, 95% CI 0.44–0.49; $p < 0.001$) and ACEi/ARB exposure (HR 0.43, 95% CI 0.42–0.45; $p < 0.001$) and a slightly larger benefit among those with high beta-blocker exposure (HR 0.37, 95% CI 0.35–0.39; $p < 0.001$) and high ACEi/ARB exposure (HR 0.39, 95% CI 0.37–0.41; $p < 0.001$), compared to those without beta-blocker or ACEi/ARB exposure. Among those 85+, there was also a decreased risk of death among those with moderate beta-blocker exposure (HR 0.56, 95% CI 0.54–0.58, $p < 0.001$) and moderate ACEi/ARB exposure (HR 0.53, 95% CI 0.52–0.55, $p < 0.001$) and a slightly larger benefit among those with high beta-blocker exposure (HR 0.43, 95% CI 0.42–0.45, $p < 0.001$) and high ACEi/ARB exposure (HR 0.45, 95% CI 0.43–0.47, $p < 0.001$). Again, to test the robustness of these findings, we ran a sensitivity analysis among beneficiaries that survived to 6 months. We determined their PDC during the first 6 months and examined time to mortality in the second 6 months. We found a similar benefit for neurohormonal therapy, again with efficacy preserved across the age spectrum (Table S3).

The cumulative incidence of mortality through 1 year of follow-up is displayed in Figure 1 (additional detail in Figure S2). There is a clear association between neurohormonal therapy exposure and decreased mortality across all levels of the age spectrum. Similar to the 30-day analysis, while the overall death rate is higher among those in the 85+ age stratum, the magnitude of mortality benefit appears preserved for both beta-blockers and ACEi/ARBs.

DISCUSSION

The landmark clinical trials which demonstrated the mortality benefits of neurohormonal therapy in HFrEF were conducted decades ago. Then, as today, clinical trial populations were not always representative of the “real-world” patient populations.¹⁹ Time has further compounded this problem because today’s HFrEF population is older and more medically complex than even 20 years ago. While neurohormonal therapy is commonly used in older patients, there is uncertainty about whether older

patients benefit as much as their younger counterparts and whether it should even be attempted in those of advanced age (>85 years). In this study, we sought to determine if the increasing age alters the risk/benefit ratio of neurohormonal therapy and, if so, how. These results will inform both clinical care and the refinement of quality metrics.^{20,21}

To date, there has been little empirical data to inform clinical practice and guide the development of nuanced quality metrics in this area. Subgroup analyses of original trial data from MERIT-HF, CIBIS-II, and the early carvedilol studies, suggested a benefit in “elderly” populations, but in these cases, “elderly” was defined as ≥ 65 years old and all post hoc analyses were limited by power and sample size.^{3,7,8}

In 2005, Flather et al. investigated the utility of nebivolol, notably not a HFrEF-specific beta-blocker, in 2128 patients aged ≥ 70 in the SENIORS trial and found a HR 0.86 (95% CI 0.74–0.99, $p = 0.039$) for the composite outcome of all-cause mortality or cardiovascular hospitalization among those exposed to nebivolol.²² In 2006, Cleland et al. randomized 850 patients ≥ 70 years old to perindopril (also not a HF-specific beta-blocker) or placebo in the perindopril in elderly people with chronic heart failure study. With 1-year follow-up data for 207 of those patients, the authors found a trend toward a reduction in the composite endpoint of all-cause mortality and HF hospitalization and a significant reduction in HF hospitalization (HR 0.63: 95% CI 0.41–0.97; $p = 0.033$).²³ In both of these studies, however, populations ≥ 80 were underpowered. In 2018, Savarese et al. published a propensity-matched, observational study of 2416 Swedish octogenarians with HFrEF and found a HR 0.78 (95% CI 0.72–0.86) for all-cause mortality and a HR 0.86 (95% CI 0.79–0.94) for all-cause mortality or heart failure hospitalization among those exposed to ACEi/ARBs.²⁴

Our study confirms and extends this prior work and fills a gap in empirical evidence. Specifically, some have questioned whether neurohormonal therapy immediately after HFrEF hospitalization is safe in older patients.²⁵ Among those aged 85+ years, we found that the mortality benefits of neurohormonal therapy outweigh the mortality risk from short-term adverse events, within 30 days of HF discharge. Similarly, there have been questions about efficacy of continuing long-term neurohormonal therapy in older patients^{25–28} As the 1-year mortality data from this study demonstrates, even in the oldest patients, the longer-term benefits of neurohormonal therapy appear well preserved over time.

Limitations

This study has important limitations. First, this study was performed using fee-for-service Medicare beneficiaries




FIGURE 1 Survival curves for death within 1 year (conditional on survival to 30 days after discharge) after hospital discharge based on beta-blocker and ACEi/ARB/ARNI exposure, stratified by age, 2008–2015. This figure shows the Kaplan–Meier curves for 1-year time to death, by age, based on exposure to beta-blockers (left side) and ACEi/ARB/ARNI (right side). Panel (A) shows the survival curves for beneficiaries aged 66–74 years. Panel (B) shows the survival curves for beneficiaries aged 75–85 years and Panel (C) shows the survival curves for beneficiaries aged 85+ years. In each panel, patients are stratified by the proportion of days covered (PDC) by relevant drug: “no” exposure, 0 PDC; “moderate” exposure, 1–80 PDC; and “high” exposure, 80+ PDC

and care should be used when extrapolating the results to other populations, including those with managed care plans. Next, it uses Medicare claims which afford a robust sample size but limit data granularity. Despite sophisticated weighting techniques, residual confounding due to the lack of vital signs and lab measurements remains a significant limitation. Importantly, however, the NNT observed in this paper for beta-blockers and ACEi/ARB in the youngest age stratum (age 66–74) is similar to composite estimates from prior randomized, controlled trials.⁴ This provides evidence

that our observational estimates align closely with prior clinical trial findings, somewhat mitigating this concern.²⁹ In addition, we calculated *E*-values, which describe how large an unmeasured confounder would have to be in order to alter the results.³⁰ For the short-term analysis, the *E*-values ranged from 1.72 to 2.32. For the long-term analysis, the *E*-values ranged from 2.26 to 3.38. To compare, we found that the HR for well-known risk factors for 30-day mortality such as renal failure (HR 1.3, 95% CI 1.28–1.32), chronic lung disease (HR 1.16, 95% CI 1.14–1.17), and

cancer (HR 1.10, 95% CI 1.07–1.13) were markedly lower. Therefore, it is unlikely that an unmeasured or unknown confounder would have a substantially greater association with mortality than these known risk factors by having a relative risk exceeding 2.26–3.38 (Table S4). Second, the short-term analysis in this project may suffer from residual immortal time bias but since our primary analysis and sensitivity checks yielded similar results, we contend that any residual bias is small. Third, in the long-term analysis, the use of the PDC as the exposure may introduce bias. However, again, since our main analysis and sensitivity check yielded similar results, any residual bias is likely small. Finally, these results reflect population-based estimates and should not supersede clinical judgment.

CONCLUSION

At a population level, after accounting for individual patient differences, patients who receive neurohormonal therapy, namely beta-blocker and ACEi/ARB, after HFREF hospitalization and then longitudinally over time have significantly lower short- and long-term mortality than those who do not, across the age spectrum. The benefit of neurohormonal therapy does not appear to wane with age. Therefore, it is reasonable for clinical guidelines and quality metrics to continue recommending neurohormonal therapy at and after hospital discharge for all HFREF patients, regardless of age.

ACKNOWLEDGMENTS

This work is supported by the National Heart Lung and Blood Institute (NHLBI) (K23HL142835 to Lauren Gilstrap); the National Institute on Aging (NIA) (P01AG019783 to Andrea M. Austin, Amber Barnato, and A. James O'Malley); American Heart Association (AHA) (18IPA34170185 to Parag Goyal); and the National Center for Advancing Translational Science (NCATS) (UL1TR001086 to Anna N. A. Tosteson). None of the funding sources (NHLBI, NIA, AHA, or NCATS) had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit for publication.

CONFLICT OF INTEREST

Jonathan S. Skinner is a consultant for Sutter Health, an investor in Dorsata, Inc., and was a consultant for the Government of Singapore. The remaining authors have no relationships with industry to report.

AUTHOR CONTRIBUTIONS

All authors meet the criteria for authorship stated in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals.

SPONSOR'S ROLE

This study was funded by the National Heart Lung and Blood Institute (K23-HL142832). The sponsor had no role in the design and conduct of this study.

ORCID

Parag Goyal  <https://orcid.org/0000-0001-7474-3737>

TWITTER

Lauren Gilstrap  @laurengilstrap

REFERENCES

1. The SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB Jr, Cohn JN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. *N Engl J Med.* 1992;327:685-691.
2. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. *N Engl J Med.* 1996;334:1349-1355.
3. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med.* 2001; 344:1651-1658.
4. Writing Committee M, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. *Circulation.* 2013;128:e240-e327.
5. American Academy of Family Physicians, American Academy of Hospice and Palliative Medicine, American Nurses Association et al. ACCF/AHA/AMA-PCPI 2011 performance measures for adults with heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on performance measures and the American Medical Association-physician consortium for performance improvement. *J Am Coll Cardiol.* 2012;59:1812-1832.
6. Center for Medicare and Medicaid Services. *Quality Measures. MACRA/MIPS: Quality Payment Program.* Washington, DC: Center for Medicare and Medicaid Services; 2017.
7. Erdmann E, Lechat P, Verkenne P, Wiemann H. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. *Eur J Heart Fail.* 2001;3:469-479.
8. Deedwania PC, Gottlieb S, Ghali JK, Waagstein F, Wikstrand JC, Group M-HS. Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. *Eur Heart J.* 2004;25:1300-1309.
9. Centers for Medicare and Medicaid Services. *Chronic conditions among medicare beneficiaries.* Washington, DC: Centers for Medicare and Medicaid Services; 2012.
10. Goyal P, Bryan J, Kneifati-Hayek J, et al. Association between functional impairment and medication burden in adults with heart failure. *J Am Geriatr Soc.* 2019;67:284-291.
11. Li Q, Glynn RJ, Dreyer NA, Liu J, Mogun H, Setoguchi S. Validity of claims-based definitions of left ventricular systolic dysfunction in Medicare patients. *Pharmacoepidemiol Drug Saf.* 2011;20:700-708.

12. Loop MS, Van Dyke MK, Chen L, et al. Comparison of length of stay, 30-day mortality, and 30-day readmission rates in Medicare patients with heart failure and with reduced versus preserved ejection fraction. *Am J Cardiol.* 2016;118:79-85.
13. ACS. *American Community Survey.* Washington, DC: US Census Bureau; 2018.
14. CDC. *Census Regions and Divisions in the United States.* Atlanta, GA: Centers for Disease Control; 2017.
15. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. *Med Care.* 1998;36:8-27.
16. Preiss D, Campbell RT, Murray HM, et al. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. *Eur Heart J.* 2015;36:1536-1546.
17. Kaiser Family Foundation. *Medicaid Enrollment by Race/Ethnicity.* Vol 2020. Oakland, CA: Kaiser Family Foundation; 2013.
18. Kim DH, Patorno E, Pawar A, Lee H, Schneeweiss S, Glynn RJ. Measuring frailty in administrative claims data: comparative performance of four claims-based frailty measures in the U.S. Medicare data. *J Gerontol A Biol Sci Med Sci.* 2020;75:1120-1125.
19. Masoudi FA, Havranek EP, Wolfe P, et al. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. *Am Heart J.* 2003;146:250-257.
20. Bonow RO, Bennett S, Casey DE Jr, et al. ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/American Heart Association task force on performance measures (Writing Committee to develop heart failure clinical performance measures) endorsed by the Heart Failure Society of America. *J Am Coll Cardiol.* 2005;46:1144-1178.
21. Bonow RO, Bennett S, Casey DE Jr, et al. ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/American Heart Association task force on performance measures (Writing Committee to develop heart failure clinical performance measures): endorsed by the Heart Failure Society of America. *Circulation.* 2005;112:1853-1887.
22. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J.* 2005;26:215-225.
23. Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. *Eur Heart J.* 2006;27:2338-2345.
24. Savarese G, Dahlstrom U, Vasko P, Pitt B, Lund LH. Association between renin-angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study. *Eur Heart J.* 2018;39:4257-4265.
25. Gilstrap LG, Snipelisky D, AbouEzzeddine O, et al. Unanswered questions in contemporary heart failure. *J Card Fail.* 2017;23:770-774.
26. Rossello X, Pocock SJ, Julian DG. Long-term use of cardiovascular drugs: challenges for research and for patient care. *J Am Coll Cardiol.* 2015;66:1273-1285.
27. Julian DG, Pocock SJ. Effects of long-term use of cardiovascular drugs. *Lancet.* 2015;385:325.
28. Grossman E, Messerli FH. Why beta-blockers are not cardioprotective in elderly patients with hypertension. *Curr Cardiol Rep.* 2002;4:468-473.
29. Prasad V, Jena AB. Prespecified falsification end points: can they validate true observational associations? *JAMA.* 2013;309:241-242.
30. Haneuse S, VanderWeele TJ, Arterburn D. Using the E-value to assess the potential effect of unmeasured confounding in observational studies. *JAMA.* 2019;321:602-603.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

Appendix S1. Supporting Information

Table S1: HF_rEF identification

Table S2: Pre/Post weighting for short- and long-term analyses

Table S3: Sensitivity analysis for short- and long-term analyses

Table S4: E-values for short and long analyses

Figure S1: Distribution of days to drug fill for those exposed to neurohormonal therapy after hospital discharge

Figure S2: Survival curves for death within 1 year after hospital discharge based on beta-blocker and ACEi/ARB/ARNI exposure, stratified by age, 2008–2015

How to cite this article: Gilstrap L, Austin AM, Gladders B, et al. The association between neurohormonal therapy and mortality in older adults with heart failure with reduced ejection fraction. *J Am Geriatr Soc.* 2021;69(10):2811–2820. <https://doi.org/10.1111/jgs.17310>